Affiliation:
1. Department of Dermatology, National Skin Centre, Singapore
2. Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Abstract
Pre-exposure prophylaxis (PrEP) with co-formulated tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) is an effective prevention strategy against sexual transmission of human immunodeficiency virus (HIV) in at-risk populations.1 It can be taken daily, or on-demand for cisgender men who have sex with men (MSM) and transwomen who have sex with men.2 In spite of this, breakthrough infections have still been reported.3,4 Additionally, despite PrEP being available in Singapore for several years, accurate Singapore data on its utilisation is lacking.5 A Singapore study in February 2018 found that only 15% of MSM on a geosocial networking application (Grindr) had used PrEP.6 However, to our knowledge, there are no published Singapore cases on PrEP failures. We present 4 such cases (Table 1).
Publisher
Academy of Medicine, Singapore